Evidence

CPSI to Rebrand as TruBridge, Inc.

Retrieved on: 
Thursday, February 22, 2024
Consulting, Data Management, Practice Management, Technology, Professional Services, Managed Care, Health, Health Technology, Data Analytics, Software, Hospitals, RCM, Growth, EHR, Evidence, Multimedia, Management

CPSI (NASDAQ: CPSI), a healthcare solutions company, today announced that the Company is rebranding and changing its name to TruBridge, Inc. (“TruBridge”).

Key Points: 
  • CPSI (NASDAQ: CPSI), a healthcare solutions company, today announced that the Company is rebranding and changing its name to TruBridge, Inc. (“TruBridge”).
  • CPSI will officially transition to TruBridge on Monday, March 4, 2024, when its common stock will begin trading on the NASDAQ Stock Market under its new ticker symbol TBRG.
  • This commitment extends to the over 1,500 clients we serve, our exceptional team of employees, and our shareholders,” added Fowler.
  • The Company will be unveiling the TruBridge brand at ViVE®2024 (Booth 1344) taking place on February 25 - 28, 2024, in Los Angeles, California.

Digital Medicine Society Convenes Industry Leaders to Streamline Path to Commercial Success for Digital Health Product Developers

Retrieved on: 
Tuesday, January 23, 2024
Roche, Digital health, Patient, ZS Associates, CTA, Dime, Consumer Technology Association, DHPS, Collection, Food and Drug Administration, ZS, University, Engagement, DHP, Digital, IEP, ACHP, Connected health, Investment, ACC, Evaluation, Risk, FDA, Evidence, Organization, Pharmaceutical industry

BOSTON, Jan. 23, 2024 /PRNewswire/ -- Today, the Digital Medicine Society (DiMe) announced it's partnering with Peterson Health Technology Institute (PHTI), ZS Associates, and other leading industry organizations to define how Integrated Evidence Plans (IEP) can be developed, optimized, and used to support the regulatory and commercial success of digital health products (DHPs) on an accelerated timeline. The goal is to streamline the pathways to successful commercialization of high-value, evidence-based DHPs, addressing the top priority reported by industry leaders in DiMe's recent Digital Health Industry Regulatory Needs Assessment: to align best practices between regulatory requirements and decision-making with downstream payers and purchasers.

Key Points: 
  • In today's rapidly evolving and maturing business landscape, addressing the challenges that arise from a lack of evidence for DHPs is crucial.
  • This latest project from DiMe will address these obstacles to help streamline the path to broad adoption of evidence-based digital health technologies, build confidence with digital health purchasing organizations, and optimize health outcomes for the greatest number of patients – all while advancing innovation in the digital health landscape.
  • "Developers have been very successful at securing FDA acceptance and market access opportunities for their digital health products (DHPs).
  • This work builds on DiMe's successful U.S. Digital Health Regulatory Pathways for DHPs and Evidence DEFINED framework to advance the use of IEPs for developing DHPs.

GLUCOTRACK ANNOUNCES SHAREHOLDER UPDATE

Retrieved on: 
Monday, November 13, 2023
Diet, Longevity, Insulin, Hypoglycemia, American Diabetes Association, Diagnosis, CGM, Insurance, Trust, CMS, Evidence, Diabetes, Growth, Doctor of Philosophy, Medicare, Himawari (satellites), Prediabetes, Clinical chemistry, Letter, BGM, Environment, Management, Medical device, Pharmaceutical industry

Rutherford, NJ, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a shareholder update letter.

Key Points: 
  • Rutherford, NJ, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a shareholder update letter.
  • In recent years, the diabetes market has experienced a significant transformation, driven by the growth of continuous glucose monitoring (CGM).
  • This was the first update to the guidelines since 2011 and included major shifts in clinical thinking.
  • In the last shareholder update, we had recognized that this would raise the regulatory bar for any non-invasive glucose sensor performance.

FDA Agrees Loyal Data Supports Reasonable Expectation of Effectiveness for Large Dog Lifespan Extension

Retrieved on: 
Tuesday, November 28, 2023
Health, FDA, Consumer, Pets, Pharmaceutical, Biotechnology, Veterinary, Great Dane, Longevity, Evidence-Based Veterinary Medicine Association, Safety, Food, Center for Veterinary Medicine, Ageing, Collection, Risk, Patient, Multimedia, Life, Veterinary medicine, Notifiable disease, Animal, Breeding, Evidence, Human, Doctor of Philosophy, VMD, Khosla Ventures, Cancer, Quality of life, Dog, Observational study, Pharmaceutical industry, Vaccine, Loyal

“Loyal was founded with the ambitious goal of developing the first drugs to extend healthy lifespan in dogs,” said Loyal CEO Celine Halioua.

Key Points: 
  • “Loyal was founded with the ambitious goal of developing the first drugs to extend healthy lifespan in dogs,” said Loyal CEO Celine Halioua.
  • It’s designed for drugs that demonstrate a reasonable expectation of effectiveness in addressing an unmet medical need, but require complex and difficult studies to complete collection of definitive effectiveness data.
  • It means the FDA agrees LOY-001 has a reasonable expectation of effectiveness and, once the FDA approves Loyal’s manufacturing and safety data packages, Loyal can market the drug for lifespan extension in the target canine population.
  • The Center for Veterinary Medicine at the FDA has reviewed Loyal’s data, results, and scientific arguments and determined they provide reasonable expectation of the drug’s effectiveness to extend canine lifespan and healthspan.

RBC ranks third overall and #1 in Canada for AI maturity out of 50 global banks

Retrieved on: 
Wednesday, November 15, 2023
Aiden, Research, NYSE, Organization, Creativity, Entrepreneurship, Privacy, Learning, Vector Institute, Espresso, Algorithm, Ecosystem, Artificial intelligence, Trust, Intelligence, Benchmarking, RBC Capital Markets, Creative, Environment, TSX, RBC, Medical device, Data science, Evidence, AI

The Evident AI Index, first issued by AI benchmarking and intelligence platform Evident in January 2023, scores financial institutions across four key pillars: talent, innovation, leadership and transparency.

Key Points: 
  • The Evident AI Index, first issued by AI benchmarking and intelligence platform Evident in January 2023, scores financial institutions across four key pillars: talent, innovation, leadership and transparency.
  • RBC was recognized by Evident for its industry-leading work around responsible and ethical AI and its commitment to AI innovation, which includes research, patents and open source activity.
  • "I'm pleased that RBC continues to be globally recognized for our AI leadership in the Evident AI Index," said Dave McKay, president and CEO, RBC.
  • "We congratulate RBC for ranking in the top three leading AI banks worldwide, and number one in Canada.

World Healthcare Data Research Report 2023: Market to Triple by 2030 - New Entrants and Incumbents are Leveraging RWD/RWE to Generate Valuable Insights

Retrieved on: 
Monday, November 13, 2023
Real-World Evidence, Drug development, Acquisition, Real, Organization, Health policy, Real world evidence, Electronic health record, RWD, Public health surveillance, Ecosystem, Health information management, Procurement, COVID-19, Flatiron, Evidence, RWE, Research report, Pharmaceutical industry, Sales, Research

The report provides valuable insights into the current and future state of the RWD/RWE market.

Key Points: 
  • The report provides valuable insights into the current and future state of the RWD/RWE market.
  • These trends are leading to a rapidly growing market, which this report forecasts will experience an average 14.6% CAGR through 2030, roughly tripling today's addressable market from $4.6B to $13.6B USD.
  • The research is relevant to any healthcare stakeholder looking to leverage real-world data for evidence-based decision making.
  • The mass digitization of healthcare records over the past decade has led to an explosion of new, highly-valued clinical data assets.

New Report From Evident Lifts the Lid on How Banks Are Driving Value From AI

Retrieved on: 
Tuesday, October 31, 2023
Professional Services, Data Management, Technology, Software, Finance, Artificial Intelligence, Banking, DBS Bank, ChatGPT, Acquisition, Research, ROI, BNP Paribas, Machine learning, EUR, JPMorgan Chase, Benchmarking, USD, Literacy, Library, AI, Automation, Dairy, Medical device, Evidence

According to Evident, a number of banks are now publicly reporting the total number of AI use cases in production, as well as the ROI from these use cases - an indication of growing AI maturity.

Key Points: 
  • According to Evident, a number of banks are now publicly reporting the total number of AI use cases in production, as well as the ROI from these use cases - an indication of growing AI maturity.
  • Many banks have established central AI leadership teams to orchestrate and support these activities.
  • As adoption of AI continues to accelerate, we will see banks leverage AI to develop deeper analysis engines.
  • To learn more about Evident, receive a copy of the Evident AI Outcomes Report or further details of the Evident AI Index , please contact the media contacts listed below.

Evident Vascular Announces Scientific Advisory Board and New Board Member

Retrieved on: 
Monday, October 30, 2023
Health, Technology, Health Technology, Artificial Intelligence, Cardiology, Biotechnology, Yee, Intelligence, Faculty, FAHA, JD, FSVM, FACC, Manatee Memorial Hospital, LLP, RPVI, Workflow, Master of Science, VIVA, IVUS, Patient, CPO, Diagnosis, Scientific Committee on Emerging and Newly Identified Health Risks, Evidence, MS, Coronavirus Scientific Advisory Board, Management, Medical imaging, MD

Evident Vascular, Inc. a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflows, announced today its Scientific Advisory Board and expansion of its Board of Directors.

Key Points: 
  • Evident Vascular, Inc. a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflows, announced today its Scientific Advisory Board and expansion of its Board of Directors.
  • “It is our privilege to have this esteemed group of clinical experts on our Scientific Advisory Board.
  • “We are also pleased to welcome Bruce Shook to the Evident Vascular Board of Directors.
  • Evident Vascular is developing the first IVUS platform designed for peripheral interventions, with enhanced ease of use and improved image quality.

API Security Trailblazer Salt Security Bolsters Leadership Team to Propel Global Growth and Innovation

Retrieved on: 
Wednesday, October 18, 2023
HP, Salt, McAfee, Organization, PALO, API, CrowdStrike, Posit, Growth, Acronis, ID, Risk, Marketing, Ecosystem, Partnership, STEP, Algorithm, CMO, Accenture, Evidence, Fine chemical

PALO ALTO, Calif., Oct. 18, 2023 /PRNewswire/ -- Salt Security, the leading API security company, today announced that Matt Quarles and Michael Callahan have joined the company as Chief Revenue Officer (CRO) and Chief Marketing Officer (CMO), respectively. Combined, Quarles and Callahan have more than four decades of experience driving business strategy and leading sales and marketing functions at both startups and public companies across the IT and cybersecurity industry. Quarles and Callahan will play a pivotal role in leading Salt Security into its next phase of growth and executing the company's global go-to-market strategy.

Key Points: 
  • Since 2016, Salt Security has led and advanced the API security market with its proven and mature API security platform.
  • Salt is the only API security solution leveraging the power of cloud-scale big data and time-tested artificial intelligence (AI) algorithms.
  • According to the Salt Labs State of API Security Report, Q1 2023 , 94% of respondents experienced security problems in production APIs in the past year.
  • "We are honored to add Matt and Michael to Salt's executive leadership team," said Michael Nicosia, COO and co-founder at Salt Security.

Insight Optix and X1 Announce Strategic Innovative eDiscovery Partnership

Retrieved on: 
Tuesday, October 17, 2023
Partnership, Metadata, Evidence, SharePoint, Warner Bros. Discovery EMEA, Relativity, Collection, OneDrive, MS 365, ESI, E5, Management, Risk management, OptiX, X1

NASHVILLE, Tenn., Oct. 17, 2023 /PRNewswire-PRWeb/ -- Insight Optix and X1 Discovery, two innovative legal technology companies, announce a strategic partnership to combat exponentially rising data volumes, and the over-preservation and over-collection practices that lead to high eDiscovery costs.

Key Points: 
  • NASHVILLE, Tenn., Oct. 17, 2023 /PRNewswire-PRWeb/ -- Insight Optix and X1 Discovery, two innovative legal technology companies, announce a strategic partnership to combat exponentially rising data volumes, and the over-preservation and over-collection practices that lead to high eDiscovery costs.
  • Despite more than a decade of industry talk about reducing discovery spend, the problem persists because there has not been enough strategic focus on the earliest stages of discovery.
  • "The partnership is a win-win for our clients and our respective teams who enjoy collaborating together to deliver such a powerful solution."
  • X1 Enterprise Collect makes targeted collection easy with a one-step upload to Relativity or a load-ready export for other review platforms.